Key Insights

Highlights

Success Rate

100% trial completion (above average)

Research Maturity

56 completed trials (90% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 62 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

19%

12 trials in Phase 3/4

Results Transparency

7%

4 of 56 completed with results

Key Signals

4 with results100% success

Data Visualizations

Phase Distribution

55Total
Not Applicable (22)
Early P 1 (1)
P 1 (8)
P 2 (12)
P 3 (9)
P 4 (3)

Trial Status

Completed56
Unknown3
Withdrawn2
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 56 completed trials

Clinical Trials (62)

Showing 20 of 20 trials
NCT01431326Completed

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT05911503Early Phase 1RecruitingPrimary

Clinical Study of High Concentration Ganciclovir Eye Drops in the Treatment of Cytomegalovirus Retinitis

NCT00001062Phase 1CompletedPrimary

A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Eyes

NCT00001034Phase 2CompletedPrimary

The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIV

NCT00000989Not ApplicableCompletedPrimary

The Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony Stimulating Factor in the Treatment of Cytomegalovirus (CMV) of the Eye in Patients With AIDS

NCT00000970Phase 1CompletedPrimary

A Study of Foscarnet Plus Ganciclovir in the Treatment of Cytomegalovirus of the Eye in Patients With AIDS Who Have Already Been Treated With Ganciclovir

NCT00000697Phase 2WithdrawnPrimary

A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Cannot Use Ganciclovir

NCT00000726Phase 1CompletedPrimary

Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome

NCT00000691Phase 2CompletedPrimary

A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure

NCT00000668Phase 1CompletedPrimary

A Phase I Pharmacokinetic and Tolerance Study of 28-Day Regimens of Oral Ganciclovir

NCT00000693Not ApplicableCompletedPrimary

Suppression of Cytomegalovirus Retinitis Utilizing High Dose Intravenous Acyclovir and Oral Zidovudine in Patients With AIDS

NCT00001061Phase 2CompletedPrimary

Comparison of Two Methods in the Treatment of Cytomegalovirus of the Eyes in Patients With AIDS

NCT00000881Phase 1Withdrawn

A Study of Cidofovir in HIV-Infected Children With Cytomegalovirus (CMV) Disease

NCT00000673Phase 1CompletedPrimary

A Phase I/II Open-Labelled Trial of Intravitreal Ganciclovir Salvage Therapy for AIDS Patients With Active CMV Retinitis Who Are Intolerant of Systemic Therapy

NCT04831333CompletedPrimary

Deep Learning-based System and AIDS-related Cytomegalovirus Retinitis

NCT00002377Phase 3CompletedPrimary

A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes

NCT00000143Phase 3CompletedPrimary

Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)

NCT00000135Phase 2Completed

Studies of the Ocular Complications of AIDS (SOCA)--Monoclonal Antibody CMV Retinitis Trial (MACRT)

NCT00000136Phase 3Completed

Studies of the Ocular Complications of AIDS (SOCA)--Foscarnet-Ganciclovir CMV Retinitis Trial (FGCRT)

NCT00000134Phase 3Completed

Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)

Scroll to load more

Research Network

Activity Timeline